Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) added 1.69% by the end of trading session at $6. For the current quarter, the 4 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$0.85/share, which would compare with -$0.7 in the year-ago quarter. The net percentage change is -64.54% over the last 12 months. The trading range in the same period had a highest hit of $23.62 while lowest level was $3.2. At the moment the price is 35.46% above its 50-day moving average and -39.56% below its 200-day moving average.

Dynavax Technologies Corporation (NASDAQ:DVAX) on March 13, 2017 reported financial results for the fourth quarter and year ended December 31, 2016. The net loss for the year ended December 31, 2016 was $112.4 million, or $2.92 per share, compared to $106.8 million, or $3.25 per share, for the year ended December 31, 2015.

The Company had $81.4 million in cash, cash equivalents and marketable securities as of December 31, 2016, compared to $196.1 million at December 31, 2015. In addition, in the first quarter of 2017 the Company received proceeds of $23.3 million from sales of common stock under an at-the-market sales agreement.

Total revenues were $7.3 million for the fourth quarter of 2016 and $11.0 million for the full year of 2016 compared to $0.7 million and $4.1 million for the same periods in 2015. The increase was primarily due to recognition of $7.2 million under the research collaboration and license agreement with AstraZeneca related to the initiation of a Phase 2a clinical trial by AstraZeneca.

Research and development expenses were $18.4 million for the fourth quarter of 2016 and $84.5 million for the full year of 2016 compared to $20.9 million and $86.9 million for the same periods in 2015. This decrease was primarily due to a reduction in outside services expense associated with the completion of the HBV-23 clinical study in the fourth quarter of 2015, partially offset by an increase in headcount as well as regulatory and manufacturing activities in preparation for the anticipated commercial launch of HEPLISAV-B.

General and administrative expenses were $8.2 million for the fourth quarter of 2016 and $37.3 million for the full year of 2016 compared to $6.7 million and $22.2 million for the same periods in 2015. This increase was primarily due to costs related to preparation for the anticipated commercial launch of HEPLISAV-B including additional headcount, information technology systems and infrastructure to support commercial development as well as costs related to sourcing a debt financing commitment.

Athersys, Inc. (NASDAQ:ATHX) last exchanged hands at a price $1.14/share, registering a decline of -0.87%. Among 4 Wall Street analysts tracked by Thomson/First Call, the average PT for ATHX is $7 but some of them are predicting the price to move at the $9 level. If the most optimistic analysts are correct, the expected total return from the current price would be 689.47. The number of shares traded in most recent trading day was 1.33M shares which averages 746.60K shares a day. Its previous fifty two week high was $2.9 and moved down -47.71% over the same time frame, currently having a market cap around $123.52 million. Shares have risen -28.75% over the trailing six months. At the moment, the stock trades -12.32% below its 50-day moving average and -36.95% below its 200-day moving average.

Athersys, Inc. (NASDAQ:ATHX) on March 9, 2017 reported its fourth quarter of 2016 and annual 2016 financial results.

Total revenues for the fourth quarter of 2016 were $1.0 million compared to $10.6 million in the same period in the prior year, reflecting the recognition of the $10.0 million license fee that we received from Chugai Pharmaceutical Company, Ltd. (“Chugai”) upon the termination of the collaboration in October 2015. This was partially offset by a $0.6 million milestone payment from Bristol-Myers Squibb Company in the fourth quarter of 2016.

Research and development expenses increased to $7.1 million in the 2016 fourth quarter from $5.3 million in the same period in the prior year, primarily due to increased clinical and preclinical development costs, which vary based on trials underway, clinical manufacturing and process development activities.

General and administrative expenses remained relatively consistent at $2.0 million in the 2016 fourth quarter, compared to $1.8 million in the corresponding 2015 period.

Net loss was $7.1 million in the fourth quarter of 2016, compared to net income of $3.6 million for the same period of 2015.  The decrease was primarily due to the $10.0 million Chugai license fee in the fourth quarter 2015 revenue.

Total revenues were $17.3 million in 2016, compared to $11.9 million in 2015, reflecting the $15.0 million license fee from Healios in 2016 and the $10.0 million license fee from Chugai that was recognized in 2015.

Research and development expenses increased to $24.8 million in 2016 from $21.3 million in 2015. The increase related primarily to an increase in clinical and process development costs, an increase in personnel costs, an increase in legal and professional fees and an increase in research supplies related to internal process development research.

General and administrative expenses were $7.8 million in 2016 compared to $7.5 million in 2015, reflecting increases in personnel costs and other outside services.

Net loss was $15.3 million in 2016, compared to $16.4 million in 2015.  The difference of $1.1 million reflects the variances above, as well as a $1.3 million non-cash change in the fair value of our warrant liabilities and a $0.7 million gain from insurance proceeds related to remediated flood damage.

Cash used in operating activities was $10.9 million and $13.8 million for full year 2016 and full year 2015, respectively.

As of December 31, 2016, we had $14.8 million in cash and cash equivalents, compared to $23.0 million at December 31, 2015. In February 2017, we sold an aggregate of 22,772,300 shares of common stock through an underwritten public offering. As a result of the offering, we received aggregate net proceeds of approximately $20.9 million.